title: The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.
authors.affiliation: Rheumatology Department, La Paz University Hospital-Idipaz, , Madrid, Spain.
authors.forename: Ch
authors.initials: Ch
authors.lastname: Plasencia
authors.forename: D
authors.initials: D
authors.lastname: Pascual-Salcedo
authors.forename: P
authors.initials: P
authors.lastname: Alcocer
authors.forename: M G
authors.initials: MG
authors.lastname: Bonilla
authors.forename: A
authors.initials: A
authors.lastname: Villalba
authors.forename: D
authors.initials: D
authors.lastname: Peiteado
authors.forename: F
authors.initials: F
authors.lastname: Arribas
authors.forename: J
authors.initials: J
authors.lastname: Díez
authors.forename: M T
authors.initials: MT
authors.lastname: Lopez-Casla
authors.forename: E
authors.initials: E
authors.lastname: Martín-Mola
authors.forename: A
authors.initials: A
authors.lastname: Balsa
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D018501:Antirheumatic Agents / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D018450:Disease Progression; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab
keywords: Anti-TNF; Rheumatoid Arthritis; Treatment